Cambridge, Mass.– eGenesis, a biotech firm pioneering human-compatible engineered organs to address the global organ shortage, has named Dr. Jay Barth as its new Chief Medical Officer. The appointment adds a seasoned clinical leader to the company’s executive team as it prepares to advance its pipeline toward key clinical milestones.
Dr. Barth brings over 25 years of experience in clinical development and medical affairs across both biotech startups and global pharmaceutical companies. Most recently, he served as Chief Medical Officer at Ascidian Therapeutics, where he was instrumental in transitioning the company’s RNA exon editing technology into clinical development.
“Dr. Barth brings a wealth of expertise to our world-class team and will play a pivotal role in executing on our upcoming clinical objectives,” said Michael Curtis, PhD, CEO of eGenesis. “His experience advancing transformative, novel therapies will be invaluable as we work to develop safe and effective organs for transplantation.”
At eGenesis, Dr. Barth will oversee clinical development strategies as the company progresses its genetically engineered organ platform toward human trials. The company’s goal is to address the critical shortage of transplantable organs through gene editing technologies that make pig organs compatible with the human immune system.
“I’m excited to join eGenesis at such a pivotal time, with several major clinical milestones on the horizon,” said Dr. Barth. “There’s an urgent need for innovation in organ transplantation, and I look forward to helping build out the company’s clinical infrastructure to advance these potentially life-saving therapies.”
Dr. Barth’s career spans a variety of leadership roles in both public and private biotech firms. Prior to his role at Ascidian, he served as CMO at Lexeo Therapeutics and Amicus Therapeutics, where he led the development of therapies for rare and orphan diseases from early stages through late-phase trials. He also held senior positions at PTC Therapeutics, Merck, Altana Pharma, and Eisai Medical Research.
Dr. Barth earned his undergraduate degree from Columbia University and his medical degree from the University of Pennsylvania School of Medicine. He is a member of the American Society of Human Genetics and the American Society of Gene & Cell Therapy, and is a published author in the fields of medicine and clinical research.
